These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Supervision of the eyes during prolonged treatment with synthetic antimalarial drugs. Results in 237 patients followed up for 4 years on the average]. Bertrand JJ; Debeyre N; Kahn MF; Ryckewaert A Presse Med (1893); 1968 Nov; 76(45):2139-42. PubMed ID: 5720115 [No Abstract] [Full Text] [Related]
27. The multifocal pattern electroretinogram in chloroquine retinopathy. Neubauer AS; Stiefelmeyer S; Berninger T; Arden GB; Rudolph G Ophthalmic Res; 2004; 36(2):106-13. PubMed ID: 15017107 [TBL] [Abstract][Full Text] [Related]
28. More thoughts about antimalarials: should one prescribe chloroquine? Esdaile JM J Rheumatol; 1999 Sep; 26(9):1868. PubMed ID: 10493663 [No Abstract] [Full Text] [Related]
29. Accuracy of Amsler grid in screening for chloroquine retinopathy. Suansilpong A; Uaratanawong S J Med Assoc Thai; 2010 Apr; 93(4):462-6. PubMed ID: 20462090 [TBL] [Abstract][Full Text] [Related]
30. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Bernstein HN Am J Med; 1983 Jul; 75(1A):25-34. PubMed ID: 6869408 [TBL] [Abstract][Full Text] [Related]
31. Chloroquine-induced ocular toxicity. Petrohelos MA Ann Ophthalmol; 1974 Jun; 6(6):615-8. PubMed ID: 4836611 [No Abstract] [Full Text] [Related]
32. RE: Microperimetry and the diagnosis of antimalarial maculopathy. Easterbrook M Can J Ophthalmol; 2014 Jun; 49(3):307-8. PubMed ID: 24862782 [No Abstract] [Full Text] [Related]
33. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Rynes RI Am J Med; 1983 Jul; 75(1A):35-9. PubMed ID: 6869409 [TBL] [Abstract][Full Text] [Related]
34. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus. Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488 [No Abstract] [Full Text] [Related]
35. [Macular complications of synthetic antimalarials. Apropos of a case]. Ducousso F; Ballion JC; Kovalski JL; Labrouze JM; Bazin S; Bourguignon G; Saliou G J Fr Ophtalmol; 1995; 18(8-9):553-8. PubMed ID: 7560802 [TBL] [Abstract][Full Text] [Related]
36. An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine. Easterbrook M J Rheumatol; 1999 Sep; 26(9):1866-8. PubMed ID: 10493662 [No Abstract] [Full Text] [Related]
37. Long-term use of antimalarial drugs in rheumatic diseases. Jover JA; Leon L; Pato E; Loza E; Rosales Z; Matias MA; Mendez-Fernandez R; Díaz-Valle D; Benitez-Del-Castillo JM; Abasolo L Clin Exp Rheumatol; 2012; 30(3):380-7. PubMed ID: 22339928 [TBL] [Abstract][Full Text] [Related]
38. Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine. Riley K; Schwager Z; Stern M; Vleugels RA; Femia A JAMA Dermatol; 2019 Apr; 155(4):491-493. PubMed ID: 30758479 [TBL] [Abstract][Full Text] [Related]
39. Ocular toxicity of antimalarial drugs. Long-term follow-up. Carr RE; Henkind P; Rothfield N; Siegel IM Am J Ophthalmol; 1968 Oct; 66(4):738-44. PubMed ID: 5729592 [No Abstract] [Full Text] [Related]
40. Chloroquine-induced retinal toxicity. Whitelaw D; Jessop S S Afr Med J; 2005 Feb; 95(2):72. PubMed ID: 15751191 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]